Treace Medical Concepts began a limited market release of its Nanoplasty 3D Minimally Invasive Bunion Correction system and procedure. Nanoplasty is billed as a revolutionary approach to minimally invasive (MIS) bunion surgery.

The Nanoplasty MIS system delivers reproducible, 3D correction of a bunion deformity via a cosmetically appealing, hidden incision of the side of the foot. The system is the company’s first entry into the metatarsal osteotomy segment.

“The Nanoplasty System is a game changer for surgeons seeking to engage the growing patient demand for MIS osteotomy bunion surgery without the complexity and steep learning curves of current MIS osteotomy systems on the market,” said surgeon design team member for the Nanoplasty system, Jonathan Kaplan, MD, Associate Chief of the Foot and Ankle Division at Duke University. “The Nanoplasty System offers surgeons an advanced, instrumented solution allowing them to reproducibly correct all three planes of the patient’s bunion deformity through a discreet 1.5 centimeter incision hidden on the side of the foot.”

Full commercial release of the Nanoplasty system is expected to occur in the first half of 2025.

“As the pioneers and leaders in 3D bunion correction with the patented Lapiplasty Procedure, we are excited to announce the limited market release of the first in our lineup of minimally invasive osteotomy solutions,” said John T. Treace, founder CEO of Treace. “The Nanoplasty Procedure allows us, for the first time, to address the large metatarsal osteotomy segment of our $5B+ US bunion market opportunity. The Nanoplasty Procedure, combined with our market-leading Lapiplasty and Adductoplasty Procedures, represents a significant milestone in our strategy to provide a comprehensive portfolio of elegantly instrumented 3D bunion solutions to address the evolving needs of surgeons and patients alike.”